
Third Harmonic Bio, Inc. (THRD) Market Cap
Third Harmonic Bio, Inc. has a market capitalization of $242.8M.
Financials based on reported quarter end 2025-03-31
Price: $5.38
โผ -0.01 (-0.09%)
Market Cap: 242.79M
NASDAQ ยท time unavailable
CEO: Natalie C. Holles
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2022-09-14
Website: https://www.thirdharmonicbio.com
Third Harmonic Bio, Inc. (THRD) - Company Information
Market Cap: 242.79M ยท Sector: Healthcare
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Analyst Sentiment
Based on 5 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 3 sources)
Consensus Price Target
Low
$4
Median
$19
High
$23
Average
$16
Potential Upside: 200.2%
Price & Moving Averages
Related Companies in Healthcare

VOYAGER THERAPEUTICS INC (VYGR)
Healthcare
$0.24B
Mkt Cap

ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT)
Healthcare
$0.24B
Mkt Cap

SPOK HOLDINGS INC (SPOK)
Healthcare
$0.24B
Mkt Cap

REPLIMUNE GROUP INC (REPL)
Healthcare
$0.24B
Mkt Cap

SIGHT SCIENCES INC (SGHT)
Healthcare
$0.23B
Mkt Cap

908 DEVICES INC (MASS)
Healthcare
$0.25B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"Headline metrics (latest quarter ended 2025-03-31): Revenue was ~0 (only ~$48k in the prior 2024-12-31 quarter), and net income was -$15.8M (EPS -0.35). YoY comparisons are directionally negative: net income loss widened vs. the prior-year quarter (2024-03-31 net income -$7.9M โ 2025-03-31 -$15.8M), while sequentially (QoQ) the loss also deepened (2024-12-31 -$13.1M โ 2025-03-31 -$15.8M). Margins were not meaningfully measurable due to near-zero reported revenue. Because THRD appears effectively pre-/near-revenue in this dataset, Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on balance-sheet resilience and cash burn signals instead. Equity remains very large relative to liabilities (~$272.6M equity vs. ~$7.2M liabilities), but total assets have been volatile: assets rose into 2024-09-30/12-31 (~$304.5M/$294.6M) and then declined by 2025-03-31 (~$279.8M). Net debt is negative (net cash) throughout, suggesting liquidity support, though continued net losses imply ongoing burn risk. Total shareholder return cannot be assessed reliably here because marketPerformance price and 1Y/6M/YTD changes are not provided (price shown as 0). Analyst valuation context: consensus target ~$16.15 vs. no usable current price in the feed."
Revenue Growth
Reported revenue is effectively near zero across most quarters (0 in 3 of the last 4 quarters; only ~$48k in 2024-12-31). QoQ/YoY revenue growth is not meaningful in this dataset.
Profitability
Net losses are persistent and worsening: net income -$15.8M (2025-03-31) vs -$13.1M (2024-12-31) QoQ and vs -$7.9M (2024-03-31) YoY. EPS remains negative; margins cannot be credibly assessed due to negligible revenue.
Cash Flow Quality
No cash flow statement is provided. However, continued net losses (-$7.9M to -$15.8M YoY) suggest ongoing cash burn. No dividend payments (yield 0) and no buyback data available.
Leverage & Balance Sheet
Balance sheet shows strong equity cushion: equity ~ $272.6M with liabilities ~ $7.2M as of 2025-03-31. Net debt is consistently negative (net cash), reducing leverage risk, though total assets declined from ~$304.5M (2024-09-30) to ~$279.8M (2025-03-31).
Shareholder Returns
Total shareholder return cannot be calculated from the provided data (marketPerformance price=0; 1Y/6M/YTD changes are N/A). No dividend yield.
Analyst Sentiment & Valuation
Consensus price target is $16.15 (median $19), but current price is unavailable in the feed, so upside/downside and implied valuation cannot be quantified.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.